| 嵌合型抗原受体T细胞治疗技术在B细胞肿瘤中的研究进展:第56届美国血液学会年会报道 |
| |
| 引用本文： | 邓碧萍,刘红星,童春容.嵌合型抗原受体T细胞治疗技术在B细胞肿瘤中的研究进展:第56届美国血液学会年会报道[J].白血病．淋巴瘤,2015(2). |
| |
| 作者姓名： | 邓碧萍 刘红星 童春容 |
| |
| 作者单位： | 河北燕达医院陆道培血液·肿瘤中心,廊坊,065201 |
| |
| 摘 要： | 嵌合型抗原受体T细胞(chimeric antigen receptorT cell,CAR-T)在B细胞肿瘤临床试验中已经显示了良好的前景,但是CAR-T的设计、肿瘤抗原的选择、T细胞的来源、CAR-T的临床应用策略等还有待进一步开发完善.CAR-T免疫细胞治疗技术是2014年第56届美国血液学会(ASH)年会的热点话题之一,其基础研究及临床试验均有突破性进展.
|
| 关 键 词： | 嵌合型抗原受体T细胞 CD19 B细胞肿瘤 美国血液学会年会 |
Progress of chimeric antigen receptor T cell immunotherapy in B cell hematologic malignancies:reports from the 56th American Society of Hematology annual meeting |
| |
| Abstract: | Chimeric antigen receptor T cell (CAR-T) therapy has shown promising perspective in clinical trails of B cell hematologic malignancies.Meanwhile,this therapy still need to be further improved in the following aspects:design of CAR-T,cancer antigens selection,T cells origin,and clinical application strategy.CAR-T immunotherapy is one of hot topics in the 56th American Society of Hematology (ASH) annual meeting.Some breakthroughs have been reported in both basic research and clinical trails. |
| |
| Keywords: | Chimeric antigen receptor T cell CD19 B cell hematologic malignancies American Society of Hematology annual meeting |
| 本文献已被 万方数据 等数据库收录！ |
